Active tension adaptation at a shortened arterial muscle length: inhibition by cytochalasin-D

Am J Physiol Heart Circ Physiol. 2011 Apr;300(4):H1166-73. doi: 10.1152/ajpheart.00009.2010. Epub 2011 Jan 14.

Abstract

Unlike the static length-tension curve of striated muscle, airway and urinary bladder smooth muscles display a dynamic length-tension curve. Much less is known about the plasticity of the length-tension curve of vascular smooth muscle. The present study demonstrates that there were significant increases of ∼15% in the phasic phase and ∼10% in the tonic phase of a third KCl-induced contraction of a rabbit femoral artery ring relative to the first contraction after a 20% decrease in length from an optimal muscle length (L(0)) to 0.8-fold L(0). Typically, three repeated contractions were necessary for full length adaptation to occur. The tonic phase of a third KCl-induced contraction was increased by ∼50% after the release of tissues from 1.25-fold to 0.75-fold L(o). The mechanism for this phenomenon did not appear to lie in thick filament regulation because there was no increase in myosin light chain (MLC) phosphorylation to support the increase in tension nor was length adaptation abolished when Ca(2+) entry was limited by nifedipine and when Rho kinase (ROCK) was blocked by H-1152. However, length adaptation of both the phasic and tonic phases was abolished when actin polymerization was inhibited through blockade of the plus end of actin by cytochalasin-D. Interestingly, inhibition of actin polymerization when G-actin monomers were sequestered by latrunculin-B increased the phasic phase and had no effect on the tonic phase of contraction during length adaptation. These data suggest that for a given level of cytosolic free Ca(2+), active tension in the femoral artery can be sensitized not only by regulation of MLC phosphatase via ROCK and protein kinase C, as has been reported by others, but also by a nonmyosin regulatory mechanism involving actin polymerization. Dysregulation of this form of active tension modulation may provide insight into alterations of large artery stiffness in hypertension.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • Actins / drug effects
  • Actins / metabolism
  • Animals
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels / drug effects
  • Calcium Channels / physiology
  • Cytochalasin D / pharmacology*
  • Femoral Artery / drug effects*
  • Muscle Contraction / drug effects*
  • Muscle Contraction / physiology
  • Muscle Tonus / drug effects
  • Muscle Tonus / physiology
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / physiology
  • Myosin Light Chains / metabolism
  • Myosin Light Chains / physiology
  • Nifedipine / pharmacology
  • Phosphorylation
  • Potassium Chloride / pharmacology
  • Rabbits
  • Thiazolidines / pharmacology
  • rho-Associated Kinases / antagonists & inhibitors

Substances

  • 2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine
  • Actins
  • Bridged Bicyclo Compounds, Heterocyclic
  • Calcium Channel Blockers
  • Calcium Channels
  • Myosin Light Chains
  • Thiazolidines
  • Cytochalasin D
  • Potassium Chloride
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • rho-Associated Kinases
  • Nifedipine
  • latrunculin B